此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

长期通气支持对肌萎缩侧索硬化患者及其家属生活质量的影响 (ALS-LTMV)

2026年9月16日 更新者:Haukeland University Hospital

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years. The patient physical and psychological sufferings in ALS are immense, and apart from Riluzole, there is no effective treatment. Care of advanced ALS have an estimated cost of 4-8 million NOK per year. Perhaps the most challenging topic of ALS care is the decision to extend ventilation support into the stages of disease that require treatment both during day and night. In these cases, treatment is clearly life-sustaining and although quality of life may be maintained, the burden of caregiving imposed upon family or health care workers is huge, regardless of tracheostomy (TIV) or non-invasive (NIV) modality.

The present study is a longitudinal questionnaire study in Norway measuring overall quality of life, health-related quality of life, and disease-specific quality of life in ALS patients, partners and children before and after the introduction of life sustaining ventilation support. The investigators aim to increase the knowledge on how life-sustaining ventilation support with NIV or TIV affects the quality of life in ALS patients, life partners and children. The results from the study may provide crucial information for clinicians and patients on one of the most difficult ethical issues of ALS treatment. The investigators anticipate that this information will facilitate a shared decision making processes, weighing benefits and disadvantages in a wider perspective.

研究概览

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Bergen、挪威
      • Lørenskog、挪威
        • 招聘中
        • Akershus University Hospital
        • 首席研究员:
          • Ola Nakken
        • 接触:
          • Ola Nakken
      • Oslo、挪威
        • 招聘中
        • Oslo University Hospital
        • 首席研究员:
          • Angelina Maniaol
        • 接触:
          • Angelina Maniaol
      • Sarpsborg、挪威、1714
        • 尚未招聘
        • Østfold Hospital Kalnes
        • 接触:
      • Stavanger、挪威
        • 招聘中
        • Stavanger University Hospital
        • 首席研究员:
          • Katrin Ruth Schlüter
        • 接触:
          • Katrin Ruth Schlüter
      • Tromsø、挪威
        • 招聘中
        • Universitetssykehuset Nord-Norge
        • 接触:
        • 接触:
        • 首席研究员:
          • Agnethe Eltoft, MD
        • 首席研究员:
          • Monica Vold, MD
      • Trondheim、挪威
        • 招聘中
        • St. Olavs Hospital
        • 接触:
          • Eivind Brønstad, MD PhD
        • 首席研究员:
          • Eivind Brønstad, MD PhD
    • Nordland
    • Vest Agder
      • Kristiansand、Vest Agder、挪威
        • 招聘中
        • Sørlandet Hospital Trust
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

8年 及以上 (孩子、成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion criteria for patients:

  1. A clinical diagnosis of probable ALS according to the revised El Escorial criteria
  2. Progression of the illness leading the consulting physician to offer treatment with LTMV
  3. Can communicate in Norwegian

Inclusion criteria for partners of ALS patients:

  1. Partner of a patient with ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
  2. Can communicate in Norwegian

Inclusion criteria for children:

  1. Children from 8 years and older having a parent who suffers from ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
  2. Can communicate in Norwegian

Exclusion criteria for patients, partners and children of ALS patients:

1. Potential participants with cognitive impairment or dementia.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:选择 LTMV 延长生命治疗的 ALS 患者及其家人

Patients that choose life prolonging treatment with long term mechanical ventilation support

有源比较器:拒绝使用 LTMV 延长生命的 ALS 患者及其家人

Patients that decline life prolonging treatment with long term mechanical ventilation support

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:At inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

At inclusion
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:3 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

3 months after inclusion
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:9 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

9 months after inclusion
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:15 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

15 months after inclusion
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:21 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

21 months after inclusion

次要结果测量

结果测量
措施说明
大体时间
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:At inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

At inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:3 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

3 months after inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:9 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

9 months after inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:15 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

15 months after inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:21 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

21 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:At inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

At inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:3 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

3 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:9 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

9 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:15 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

15 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:21 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

21 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:At inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

At inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:3 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

3 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:9 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

9 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:15 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

15 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:21 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

21 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:At inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

At inclusion
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:3 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

3 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:9 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

9 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:15 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

15 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:21 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

21 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:At inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

At inclusion
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:3 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

3 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:9 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

9 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:15 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

15 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:21 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

21 months after inclusion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年4月21日

初级完成 (估计的)

2032年8月21日

研究完成 (估计的)

2032年8月21日

研究注册日期

首次提交

2023年1月30日

首先提交符合 QC 标准的

2023年2月21日

首次发布 (实际的)

2023年2月27日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅